PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced the launch of ABILIFY® (aripiprazole) Injection, an injectable ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc. (OAPI) and Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has expanded the label of ...

Abilify Maintena, an atypical antipsychotic, is currently available as an intramuscular depot formulation of aripiprazole for the treatment of schizophrenia. It is a sterile lyophilized powder that, ...

ABILIFY MAINTENA (aripiprazole) 300mg and 400mg ext-rel injectable suspension Lundbeck and Otsuka announced that the Food and Drug Administration (FDA) has expanded the label of Abilify Maintena ...

The extended-release formulation of aripiprazole (Abilify Maintena, Otsuka Pharmaceutical Co, Ltd, and H. Lundbeck A/S) has been approved by the US Food and Drug Administration (FDA) for use as an ...

NEW YORK CITY -- An investigational 1-day aripiprazole initiation regimen was comparable in efficacy to usual treatment, according to a phase I study presented here. For the treatment of schizophrenia ...

According to the National Institute on Minority Health and Health Disparities (NIMHD), less than half of all Americans who have a mental disorder get proper treatment, and less than 10% of patients ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration (FDA) ...

Please provide your email address to receive an email when new articles are posted on . Otsuka Pharmaceutical, Inc. and Lundbeck recently announced the FDA expanded the label of Abilify Maintena for ...

Otsuka Pharmaceutical Co. Ltd. and Lundbeck recently announced the FDA approved extended-release injectable suspension Abilify Maintena for maintenance monotherapy of bipolar I disorder in adults.

Approval provides patients with schizophrenia the ability to access the efficacy and safety profile of oral aripiprazole in a once-monthly formulation. Relapse prevention is an important consideration ...